Ixekizumab

Ixekizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL-17a
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 1143503-69-8 N
ATC code None
Chemical data
Formula C6492H10012N1728O2028S46 
Mol. mass 146.2 kDa
 N(what is this?)  (verify)

Ixekizumab is a humanized monoclonal antibody used in the treatment of autoimmune diseases.[1]

Ixekizumab was developed by Eli Lilly and Co.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf. 
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • Olokizumab
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)